Introduction
Mitogen-activated protein (MAP) kinases, also known as extracellular signal-regulated kinases (ERKs), [1] [2] [3] [4] [5] form a family of protein kinases that are activated by numerous extracellular stimuli of growth factors and cytokines in various cell lineages. In experimental models, p42 mapk (ERK2) has been presumed to play a significant role in cell growth and inhibition of apoptotic cell death. 1, 5, 6 The upstream components of MAP kinase pathway contain the GTP-binding protein p21 Ras which binds to the c-Raf protein kinase; Raf has been shown to phosphorylate and activate MAP kinase kinase, also known as MEK, a dual specificity kinase that phosphorylates MAP kinases on both threonine and tyrosine residues. [7] [8] [9] [10] Approximately 10-20% of patients with AML reportedly have mutated N-Ras genes. [11] [12] [13] [14] We have reported in a previous study that 50% of AML exhibited constitutive activation of MAP kinase pathway and that the activation might possibly be generated upstream of MAP kinase. MAP kinase could be activated at multiple stages from receptors to transduction components in cytoplasmic region. A number of hematopoietic growth factors (HGFs) such as IL-3, GM-CSF, SF and IL-6 stimulate MAP Correspondence: M Towatari, First Department of Internal Medicine, Nagoya University School of Medicine, Tsurumai-cho 65, Showa-ku, Nagoya 466-8550; Japan; Fax: 81 52 744 2161 Received 7 September 1998; accepted 16 December 1998 kinase pathway. [15] [16] Autocrine growth factor stimulation, for example, can be a major cause for the constitutive activation and be a critical step in leukemogenesis. 17 Another possible candidate is mutated Ras which should lie upstream of Raf-MAP kinase kinase-MAP kinase. We found that two AML samples out of 10 ERK2-positive leukemia samples had N-Ras mutations in the hot spots. 18 However, the question still remained to be resolved as to whether all AML samples with functional Ras mutations actually constitutively activate MAP kinase pathway in vivo.
In the present study, to elucidate the effect of Ras mutations on the activation of MAP kinase pathway and to consider the relevance of Ras mutations in AML, we analyzed, as an initial step, the phosphorylation status of MAP kinase (ERK2) in 22 AML cases with a single or double mutations of N-Ras gene. 19 The results were contrasted with those in pancreatic adenocarcinoma cases with K-Ras mutation at codon 12. To our knowledge, this is the first study that shows the discrepancy between mutations of Ras gene and activation of MAP kinase pathway in hematological malignancies.
Materials and methods

Cells
We used six AML samples (designated as AML1 to AML6) with mutations in N-Ras gene which had been confirmed by sequencing, previously frozen by a controlled-rate freezer to −80°C and stocked in liquid nitrogen as described previously. 19 We further found 16 more AML cases (designated as AML7 to AML22) with N-Ras mutations among more than 100 AML isolates by the same methods (unpublished data). The clinical data and the mutations of N-Ras gene are presented in Table 1 . Samples were subjected to quick thawing and extraction of whole cell lysate. Viability was assessed by the trypan blue exclusion test. All acute leukemia samples contained over 80% blast cells with viability over 80%. Whole cell lysates were extracted as reported previously. 18 Concisely, the cells were lysed in RIPA buffer (20 mm TrisHCl, pH 8.0, 0.4 m NaCl, 1% Nonidet P-40, 0.1% sodium deoxycholate, 0.1% sodium lauryl sulfate (SDS), 1 mm EDTA) containing 20 g/ml aprotinin, 20 g/ml leupeptin, 1 mm benzamidine, 1 mm phenylmethylsulfonyl fluoride (PMSF), 3 mm sodium vanadate and 40 mm sodium pyrophosphate. After incubating for 1 h at 4°C, an equal volume of RIPA buffer without NaCl was added to the extracts followed by centrifugation at 17 000 g for 20 min. The concentration of the lysates was examined by a commercial kit (Bio-Rad Protein Assay, Bio-Rad, Munich, Germany). An equal amount of the protein was used for Western blotting.
Three samples with N-Ras mutations and a sample without N-Ras mutations were thawed and resuspended with RPMI 1640 containing 10% fetal calf serum. Aliquots of cells were 
stimulated with G-CSF, IL-3 and GM-CSF separately at 37°C for 10 min. Cells were centrifuged and the pellets were directly boiled in the sample buffer followed by immunoblot analysis.
From four resected cases of pancreatic head carcinoma, 20, 21 the tumor tissues which had been snap-frozen and stored at −80°C were directly homogenized and lysed with RIPA buffer. The concentration of the lysates was examined and equal amounts of the total protein were subjected to Western blotting as described above.
Western blot analysis
The SDS polyacrylamide gel for resolving the mobility shift between the phosphorylated form and unphosphorylated form of ERK contained low bisacrylamide as we described previously. 18 The bands were detected by either an anti-ERK2 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-phospho MAP kinase antibody which recognizes both phosphorylated ERK1 and phosphorylated ERK2 (New England Biolabs, Beverly, MA, USA), or anti-actin antibody (Boehringer Mannheim, Mannheim, Germany) followed by ECL kit (Amersham, Buckinghamshire, UK).
MAP kinase activity
Activity of MAP kinase of extracted whole cell lysate was determined as we described previously. 18 In brief, equal amounts of lysates were incubated with synthesized peptide of specific substrate for ERK1 and ERK2 using a commercial kit (BIOTRAK MAP kinase assay; Amersham). MAP kinase activity was presented by an incorporated radioactivity.
Results
In the present study, we analyzed 22 AML samples in which the existence of N-Ras mutations were confirmed by sequencing. Patient characteristics and N-Ras mutations are shown in Table 1 . Equal amounts of whole cell lysates were subjected to SDS-PAGE and then transferred to the PVDF membrane followed by immunoblotting with a polyclonal antibody against ERK2. The quality and quantity of each lysate were confirmed by SDS-PAGE followed by immunoblot analysis with antiactin antibody. MAP kinases are activated when they are phosphorylated at both threonine and tyrosine residues by MEKs, and the phosphorylated form of MAP kinase migrates slower than the unphosphorylated form due to this gel system. 22, 23 Normal bone marrow samples invariably exhibit no detectable phosphorylated form of ERK2. 18 Unexpectedly, only two of 22 AML samples with N-Ras mutations showed ERK2 phosphorylation, while phosphorylated ERK2 was actually detectable in certain AML cases without N-Ras mutations. Representative data of 12 samples were shown (Figure 1a and b, and Figure 2 upper and lower panel). This was confirmed by repeated preparation of whole cell lysates of the samples in Figure 1 followed by immunoblotting (data not shown). As we reported previously, approximately 50% of the stocked samples in the same conditions showed ERK2 activation.
We then examined the phosphorylation of ERK1 in the representative 12 samples. ERK1 phosphorylation was tightly correlated with ERK2 phosphorylation, revealed by dual detection of phosphorylated ERK1 and phosphorylated ERK2 with anti-phospho MAP kinase-specific antibody (Figure 2 , middle panel). A summary of molecular studies is shown in Table 1 . We further examined the activity of MAP kinase in these lysates by in vitro phosphorylation of specific substrate for ERK1 and ERK2. As shown in Figure 3 , the activity was well paral- Table 1 , respectively; lanes 9-12, PK1-4 in Table 1 leled with the phosphorylation status in AML cases examined. The 11 leukemia samples with N-Ras mutations and no phosphorylated forms of ERK2 (AML1 to AML11) simply showed background levels, while other leukemia samples with hyperphosphorylated ERK2 including AML12 showed over 20-fold higher MAP kinase activity.
Three samples (AML1, AML2 and AML8) which exhibited N-Ras mutations but not MAP kinase activation were each stimulated with IL-3, GM-CSF and G-CSF, separately: the concentration of each cytokine was 50 ng/ml. No samples stimulated with each cytokine exhibited induced ERK2 phosphorylation. In contrast, a control AML sample without N-Ras mutations showed a prominent ERK2 phosphorylation with G-CSF stimulation for 10 min. The ERK2 phosphorylation was tightly correlated with MAP kinase activity. The experiments were performed at least twice and consistent results were obtained. Representative data are shown in Figure 4a and b. The results suggest that the activation of classical MAP kinase pathway by exogenous cytokines may be inhibited in some of the samples with N-Ras mutations.
To further explore the significance of this discrepancy between Ras mutations and activation of MAP kinase in AML, we then examined MAP kinase activation in primarily resected pancreatic carcinoma tissues which had been revealed to have K-Ras mutations. 20, 21 Pancreatic carcinoma is one of the representative solid tumors in which the role of K-Ras gene abnormality in tumor progression has been well documented. 24 MAP kinase was activated (phosphorylated) in all four tumor tissues examined, while the MAP kinase activity was at a basal level in a pancreatic carcinoma case without K-Ras mutations (Figures 1 and 3) . This suggests that, in contrast to AML cases, MAP kinase pathway is constitutively activated in association with mutated K-Ras gene in pancreatic carcinoma cells.
Figure 2
Phosphorylation of MAP kinase (ERK1 and ERK2) in AML with N-Ras mutations. Equal amounts of whole cell lysates were subjected to SDS-PAGE followed by immunoblot analysis with anti-ERK2 antibody (upper panel), anti-phospho MAP kinase antibody (middle panel), and anti-actin antibody (lower panel), respectively. Lanes 1-6 of each panel correspond to AML7 to AML12, respectively. The slower migrating band of upper panel represents the phosphorylated form of ERK2. In the middle panel, the slower migrating band (phospho ERK1) and the faster migrating band (phospho ERK2) represent phosphorylated forms of ERK1 and ERK2, respectively.
Discussion
In the present study, we showed N-Ras mutations did not always lead to the activation of MAP kinase in AML cases in contrast to pancreatic carcinoma cases. The results obtained were quite controversial concerning the widely accepted idea that activated N-Ras mutants must activate MAP kinase signal transduction pathway. However, the data which sustain the hypothesis were usually drawn from experimental models and little was known about the association of Ras mutations and MAP kinase activity in human primary tumor cells. This is, as far as we know, the first report that shows the discrepancy between mutations of Ras genes and the activation of MAP kinase pathway in human leukemia cells.
The different contribution of Ras gene mutations of MAP kinase activation may be caused by the innate biological differences between the diseases. In solid tumor cells such as pancreatic carcinoma, Ras gene mutations occur during the accumulative process of gene alterations. Constitutive activation of MAP kinases would be associated with tumor growth MAP kinase activity in AML and pancreatic carcinoma with mutations of Ras genes. MAP kinase activity was assessed by in vitro phosphorylation using the ideal substrates for ERK1 and ERK2. MAP kinase activity was represented by an incorporated 32 P-ATP. Lanes 1-13 correspond to each lane of the same number in Figure  1a , respectively. and/or escape from apoptotic cell death. In AML, however, many studies suggest that Ras gene mutations occur at a late stage and are not indispensable during the course of the disease. Although Ras mutations may be significant for disease progression in a distinct period, the next clonal evolution may decrease its functional significance. A recent report showed that, using human CD34 + progenitor cells expressing mutant N-Ras, erythroid progenitor cells carrying mutant N-Ras exhibited a proliferative defect resulting in erythroid dysplasia. 25 Constitutive activation of Ras does not mediate a mitogenic signal for erythroblasts. The authors speculate a possible link between activation of Ras and suppression of cytokine signaling through the activation of phosphotyrosine phosphatases, such as SHP-1, by mutated Ras. 26 This may be consistent with our data that any stimulation of three AML samples possessing mutated N-Ras with either G-CSF, GM-CSF or IL-3 failed to phosphorylate ERK2. This indicates the importance of exploring the involvement of the phosphatases for MAP kinase pathway such as MAP kinase phosphatases (MKP-1 and MKP-2); a recent study demonstrated positive feedback regulation of Raf-1 by the MKP-1. 27 While the involvement of mutated Ras may be clearer in myelodysplastic syndrome cases during the progression to overt leukemia 28 than in de novo AML cases, future examination of the association between the appearance of Ras mutations and activation or inactivation of MAP kinase pathway at the single cell level may prove significant.
We need to pay considerable attention to the possibility that the mutated Ras could activate different pathways from the classical MAP kinase pathway. Recent reports indicated that Ras stimulates both the MAP kinase pathway and Rho family GTPases pathway. 29 Thus, Ras lies upstream of the superfamily of MAP kinase, such as Jun kinase (JNK) and p38MAP kinase. Ras may also activate Akt in a phosphatidylinositol 3-kinase-dependent manner. 30 A large-scale study is to be performed to explore the real targets of mutated Ras other than MAP kinase in AML at the single cell level.
The rising suspicion of the relevance of the mutations of Ras genes may also ask the question whether the Ras mutations really affect clinical results of AML. The clinical importance of Ras gene mutations in the prognosis of leukemia patients has been controversial and remained to be resolved.
11,31 Now we know mutated Ras does not always activate classical MAP kinase pathway. This may clearly deny the possibility that mutations of Ras genes consistently contribute to response to chemotherapy or feasibility to relapse in adult AML through the activation of MAP kinase pathway. In analyzing the contribution of Ras gene mutations to the prognosis of AML, we may have to re-categorize the group of AML with Ras mutations into subgroups using the additional factors. The importance of searching the subsequent targets (components and signal transductions) of activated (mutated) Ras in AML, if any, are further to be emphasized.
